Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Hemasure

This article was originally published in The Gray Sheet

Executive Summary

Hemasure: Files registration statement with the Securities and Exchange Commission for a proposed $28 mil. offering of 2.5 mil. shares of common stock. Smith Barney and Volpe, Welty & Co are managing the offering. Proceeds are expected to be used for marketing and manufacturing of the Marlborough, Massachusetts-based firm's LeukoNet pre-storage leukoreduction filtration system, cleared by FDA in June ("The Gray Sheet" Jan. 9, In Brief). Hemasure says funds also are tabbed for "conducting preclinical and clinical trials of its SteriPath blood pathogen inactivation system," R&D and "regulatory approvals for other planned products," and for general corporate purposes and working capital...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel